UW-Madison biomanufacturer offers essential gene-transfer capacity

Adeno-associated virus (AAV) is used to insert replacement genes, and its role in genetic therapy trials is expanding quickly, says Carl Ross, managing director of Waisman Biomanufacturing. The AAV production reflects the Waisman lab’s growing importance in the biopharma business, as it’s the only facility on campus meeting FDA “good manufacturing practices” rules for large-scale manufacturing of biological therapies.

Waisman Biomanufacturing to be part of UW-Madison partnership in $20 million cell-based therapy center

Waisman Biomanufacturing and Waisman affiliate investigators Randolph Ashton and Krishanu Saha will be part of a new engineering research center that will develop transformative tools and technologies for the consistent, scalable and low-cost production of …

The Wisdom of Waisman

It has always been a challenge to describe the Waisman Center on the University of Wisconsin–Madison campus. This is due in part to the very nature of the research conducted at the facility, which claims as its mission “the advancement of knowledge about human development, developmental disabilities and neurodegenerative diseases through the life span.”